

# Morris J Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633322/publications.pdf>

Version: 2024-02-01

78  
papers

10,748  
citations

109321

35  
h-index

69250

77  
g-index

81  
all docs

81  
docs citations

81  
times ranked

18044  
citing authors

#	ARTICLE	IF	CITATIONS
1	CTNNB1-Mutant Aldosterone-Producing Adenomas With Somatic Mutations of GNA11/GNAQ Have Distinct Phenotype and Genotype. <i>Journal of the Endocrine Society</i> , 2021, 5, A65-A66.	0.2	0
2	Development of [ <sup>18</sup> F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9321-9329.	6.4	19
3	CONNed in Pregnancy. <i>Hypertension</i> , 2021, 78, 241-249.	2.7	2
4	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. <i>Nature Genetics</i> , 2021, 53, 1360-1372.	21.4	37
5	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1147-1149.	27.0	56
6	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , 2021, 600, 675-679.	27.8	353
7	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020, 41, 1606-1607.	2.2	18
8	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. <i>Hypertension</i> , 2019, 74, 1152-1159.	2.7	15
9	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019, 51, 636-648.	21.4	112
10	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 464-475.	11.4	206
11	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. <i>Nature Genetics</i> , 2018, 50, 1412-1425.	21.4	924
12	Investigation of primary aldosteronism in patients with resistant hypertension – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 600-601.	11.4	4
13	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. <i>PLoS ONE</i> , 2018, 13, e0198166.	2.5	94
14	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. <i>Nature Genetics</i> , 2017, 49, 403-415.	21.4	492
15	NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)-Mediated Secretion of Aldosterone. <i>Hypertension</i> , 2017, 70, 357-364.	2.7	17
16	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	21.4	470
17	Novel Mechanism for Buffering Dietary Salt in Humans. <i>Hypertension</i> , 2017, 70, 930-937.	2.7	58
18	Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. <i>Hypertension</i> , 2017, 70, .	2.7	123

#	ARTICLE	IF	CITATIONS
19	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-blind Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	74
20	Rapid Diagnosis of Primary Aldosteronism. <i>Hypertension</i> , 2017, 70, 247-249.	2.7	3
21	Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). <i>Hypertension</i> , 2017, 69, 189-196.	2.7	48
22	Primary aldosteronism as a public health issue – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 973-974.	11.4	2
23	Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations. <i>New England Journal of Medicine</i> , 2016, 374, 1492-1494.	27.0	19
24	Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 805-807.	11.4	8
25	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. <i>Nature Genetics</i> , 2016, 48, 1151-1161.	21.4	261
26	Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues. <i>Hypertension</i> , 2016, 68, 1424-1431.	2.7	33
27	Regulation of aldosterone secretion by Cav1.3. <i>Scientific Reports</i> , 2016, 6, 24697.	3.3	30
28	Telling Tails. <i>Hypertension</i> , 2016, 68, 11-16.	2.7	6
29	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 136-147.	11.4	99
30	Primary Aldosteronism: the spectre of cure. <i>Clinical Endocrinology</i> , 2015, 82, 785-788.	2.4	4
31	DACH1, a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor- $\beta$ Signaling and Suppresses Aldosterone Secretion. <i>Hypertension</i> , 2015, 65, 1103-1110.	2.7	24
32	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. <i>BMJ Open</i> , 2015, 5, e008086.	1.9	7
33	New genetic loci link adipose and insulin biology to body fat distribution. <i>Nature</i> , 2015, 518, 187-196.	27.8	1,328
34	Role of ANO4 in regulation of aldosterone secretion in the zona glomerulosa of the human adrenal gland. <i>Lancet</i> , 2015, 385, S62.	18.7	12
35	Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?. <i>Trials</i> , 2015, 16, 80.	1.6	32
36	LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E836-E844.	3.6	32

#	ARTICLE	IF	CITATIONS
37	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. <i>BMJ Open</i> , 2015, 5, e008951.	1.9	13
38	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet</i> , The, 2015, 386, 2059-2068.	13.7	904
39	Pregnancy, Primary Aldosteronism, and Adrenal <i>CTNNB1</i> Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 1429-1436.	27.0	123
40	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: Figure 1. <i>BMJ Open</i> , 2015, 5, e007645.	1.9	10
41	Clinical Value of Plasma Renin Estimation in the Management of Hypertension. <i>American Journal of Hypertension</i> , 2014, 27, 1013-1016.	2.0	5
42	Resistant hypertension: resistance to treatment or resistance to taking treatment?. <i>Heart</i> , 2014, 100, 821-822.	2.9	12
43	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. <i>American Journal of Human Genetics</i> , 2014, 94, 349-360.	6.2	158
44	Ins and Outs of Aldosterone-Producing Adenomas of the Adrenal. <i>Hypertension</i> , 2014, 63, 24-26.	2.7	10
45	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014, 46, 1173-1186.	21.4	1,818
46	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. <i>Nature Genetics</i> , 2014, 46, 826-836.	21.4	281
47	Somatic mutations in <i>ATP1A1</i> and <i>CACNA1D</i> underlie a common subtype of adrenal hypertension. <i>Nature Genetics</i> , 2013, 45, 1055-1060.	21.4	446
48	Microarray, qPCR, and <i>KCNJ5</i> Sequencing of Aldosterone-Producing Adenomas Reveal Differences in Genotype and Phenotype between Zona Glomerulosa- and Zona Fasciculata-Like Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E819-E829.	3.6	164
49	Evaluation of the Sensitivity and Specificity of <sup>11</sup> C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 100-109.	3.6	203
50	Platt versus Pickering: what molecular insight to primary hyperaldosteronism tells us about hypertension. <i>JRSM Cardiovascular Disease</i> , 2012, 1, 1-8.	0.7	1
51	Navigating the shoals in hypertension: discovery and guidance. <i>BMJ</i> , The, 2012, 344, d8218-d8218.	6.0	23
52	Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. <i>Lancet</i> , The, 2011, 377, 312-320.	13.7	149
53	The choice of diuretic in hypertension: saving the baby from the bathwater. <i>Heart</i> , 2011, 97, 1547-1551.	2.9	7
54	Heterogeneity of Blood Pressure Response to Therapy. <i>American Journal of Hypertension</i> , 2010, 23, 926-928.	2.0	15

#	ARTICLE	IF	CITATIONS
55	Success and failure of vaccines against renin-angiotensin system components. <i>Nature Reviews Cardiology</i> , 2009, 6, 639-647.	13.7	33
56	Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 646-652.	2.4	14
57	Therapeutic Potential of Vaccines in the Management of Hypertension. <i>Drugs</i> , 2008, 68, 2557-2560.	10.9	10
58	Response to Letter Regarding Article, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio." <i>Circulation</i> , 2008, 117, .	1.6	1
59	Renin: friend or foe?. <i>Heart</i> , 2007, 93, 1026-1033.	2.9	74
60	AT2 Receptor Stimulation May Halt Progression of Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 436-443.	3.8	5
61	Hypertension and ethnic group. <i>BMJ: British Medical Journal</i> , 2006, 332, 833-836.	2.3	107
62	Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. <i>Clinical Science</i> , 2004, 107, 167-173.	4.3	106
63	A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS. <i>British Heart Journal</i> , 2003, 89, 687-694.	2.1	9
64	A Genome-Wide Search For Susceptibility Loci to Human Essential Hypertension. <i>Hypertension</i> , 2000, 35, 1291-1296.	2.7	84
65	Pathoetiology, Epidemiology and Diagnosis of Hypertension. <i>Drugs</i> , 2000, 59, 1-12.	10.9	37
66	Association of the G s $\beta$ Gene With Essential Hypertension and Response to $\beta$ -Blockade. <i>Hypertension</i> , 1999, 34, 8-14.	2.7	136
67	Selective $\beta$ 1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium. <i>British Journal of Pharmacology</i> , 1999, 128, 135-141.	5.4	8
68	Optimisation of antihypertensive treatment by crossover rotation of four major classes. <i>Lancet</i> , The, 1999, 353, 2008-2013.	13.7	323
69	Who Manages Hypertensive Patients? The Primary Care-Hospital Interface1. <i>American Journal of Hypertension</i> , 1998, 11, 740-743.	2.0	0
70	The causes of essential hypertension. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 21-27.	2.4	32
71	Blood Pressure and the M235T Polymorphism of the Angiotensinogen Gene. <i>Hypertension</i> , 1996, 28, 907-911.	2.7	64
72	Expression of the $\beta$ 1- and $\beta$ 2-Subunits of the Stimulatory and Inhibitory G-Proteins in $\beta$ 1-Adrenoceptor-Blocked and non- $\beta$ 2-Adrenoceptor-Blocked Human Atrium. <i>Clinical Science</i> , 1995, 88, 571-580.	4.3	7

#	ARTICLE	IF	CITATIONS
73	Differences in Transcription and Translation of Long and Short GSI±, the Stimulatory G-Protein, in Human Atrium. <i>Clinical Science</i> , 1995, 89, 487-495.	4.3	9
74	A 5â€hydroxytryptamine receptor in human atrium. <i>British Journal of Pharmacology</i> , 1990, 100, 879-885.	5.4	178
75	Binding Sites for 125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography. <i>Clinical Science</i> , 1989, 77, 129-131.	4.3	50
76	Adrenaline and Alpha<sub>2</sub>â€Adrenoceptors in Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 63, 16-20.	0.0	1
77	Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. <i>Clinical Science</i> , 1988, 74, 359-363.	4.3	37
78	A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig <i>in vitro</i>. <i>British Journal of Pharmacology</i> , 1987, 91, 687-691.	5.4	27